anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PURPOSE: To obtain the subject formulation by mixing a hardly water-soluble pharmacologically active substance with carbomer, molding the mixture to a granular shape and covering the resultant granules with a dispersed solution containing a water-swelling acrylic polymer and a water-soluble hydroxylated cellulose derivative. CONSTITUTION: The objective covered granule having 0.5-2.5mm (preferably 0.7-1.2mm) diameter is obtained by providing a granule containing 100 pts. of a hardly water-soluble pharmacologically active substance (e.g. nifedipine, spironolactone, griseofulvin or glibenclamide) and at least 20 pts. (preferably 100-300 pts.) of carbomer and covering the resultant granule with a dispersed solution containing 100 pts. of a water-insoluble and water-swelling acrylic polymer and 20-70 pts. (preferably 20-40 pts.) of a water-soluble hydroxylated cellulose derivative. This formulation combinedly has both quick dissolution of the active component and continuous releasability of the active component for about 24hrs. A weight of the covering material is 2-10wt.% of the inside granule.
Purpose/Background: To study the feasibility and inflammatory response of surgery for rectus muscles using a small single bulbar conjunctival incision posterior and parallel to the muscle insertion.

Methods: Patients requiring surgery of at least one rectus muscle with several diagnoses, operated under general or topical / sub-Tenon's anesthesia, who had no previous eye muscle surgery, are included. Routinary clinical ophthalmological examination is carried out. After applying a 5-0 PGA traction suture, a 3-4 mm single conjunctival incision posterior and parallel to the rectus muscle insertion will be done. A hang-back recession with 6-0 PGA suture will be carried out, and the conjunctiva closed by an 8-0 PGA single stitch. The main outcome measure is duration of swelling and hemorrhage, and secondary outcome measure is motor outcome at 2 months after surgery. Results are compared with retrospectively collected data of patients operated using limbal (n= 20) and fornix incision (n= 21) as a point of reference.
Coronary artery disease (CHD) remains to be a leading cause of death in most countries (1) (2). It is well known that reducing cholesterol level by statin therapy is associated with significant reduction in plaque burden. REVERSAL (3) and ASTEROID (4) trials showed that in patients with coronary artery disease lipid-lowering with atorvastatin or rosuvastatin respectively reduced progression of coronary atherosclerosis and even cause repression of some lesions. CHD clinical events are related to plaque instability due to lipid content within the atherosclerotic plaque. High dose atorvastatin has shown to reduce the plaque lipid contents on serial IVUS analysis at 12 months. Therefore reduction in lipid content and thereby the plaque burden by lipid lowering therapy may stabilize the plaque and reduce cardiovascular events. High sensitivity C-reactive Protein (HsCRP) is an inflammatory biomarker that independently predicts future vascular events. In JUPITER (5) trial rosuvastatin (Crestor) significantly reduced the incidence of major cardiovascular events in apparently healthy people with elevated HsCRP. IVUS was utilized to demonstrate change in coronary artery vessel wall morphology over a relatively short period of time, but provided no data on the lipid content in the vessel wall. The application of NIR spectroscopy to identify lipid deposition within coronary arteries has been validated in ex vivo studies. Infrared spectra are collected as follows: Light of discrete wavelengths from a laser is directed onto the tissue sample via glass fibers. Light scattered from the samples is collected in fibers and launched into a spectrometer. The plot of signal intensity as a function of wavelength was used to develop chemometric models to discriminate lipid-cores from non-atherosclerotic tissue, and from atherosclerotic tissue that is predominantly fibrotic and from blood elements.
First of all, according to the patient's weight and ECOG score, patients were divided into three groups（the initial dose of 250 mg qd,250 mg/500 mg qd by turns, 500 mg qd）. in two weeks, if the patient who is intolerant of the initial dose,250mg qod,250mg qd ,250mg qd was selected. if the patient can tolerate the dose well,a high-dose was given,and the maximum dose does not exceeding 750mg qd.
NSAIDs, including ketoprofen, can cause serious skin adverse reactions such as exfoliative dermatitis, Stevens-Johnson Syndrome (SJS), and toxic epidermal necrolysis (TEN), which can be fatal. NSAIDs can also cause fixed drug eruption (FDE). FDE may present as a more severe variant known as generalized bullous fixed drug eruption (GBFDE), which can be life-threatening. These serious events may occur without warning. Inform patients about the signs and symptoms of serious skin reactions, and to discontinue the use of ketoprofen extended-release capsules at the first appearance of skin rash or any other sign of hypersensitivity. Ketoprofen extended-release capsules are contraindicated in patients with previous serious skin reactions to NSAIDs (see CONTRAINDICATIONS).
Obesity is associated with chronic inflammation in the central nervous system (CNS), and neuroinflammation has been shown to have detrimental effects on mood and cognition. The growth hormone secretagogue receptor (GHSR), the biologically relevant receptor of the orexigenic hormone ghrelin, is primarily expressed in the brain. Our previous study showed that neuronal GHSR deletion prevents high-fat diet-induced obesity (DIO). Here, we investigated the effect of neuronal GHSR deletion on emotional and cognitive functions in DIO. The neuron-specific GHSR-deficient mice exhibited reduced depression and improved spatial memory compared to littermate controls under DIO. We further examined the cortex and hippocampus, the major regions regulating cognitive and emotional behaviors, and found that the neuronal deletion of GHSR reduced DIO-induced neuroinflammation by suppressing proinflammatory chemokines/cytokines and decreasing microglial activation. Furthermore, our data showed that neuronal GHSR deletion suppresses neuroinflammation by downregulating AMPK-autophagy signaling in neurons. In conclusion, our data reveal that neuronal GHSR inhibition protects against DIO-induced depressive-like behavior and spatial cognitive dysfunction, at least in part, through AMPK-autophagy signaling-mediated neuroinflammation.
PROBLEM TO BE SOLVED: To provide a solution to several problems associated with cell transplantation protocols.SOLUTION: A device includes a scaffold composition and a bioactive composition incorporated into or coating the scaffold composition so that the scaffold composition and/or the bioactive composition can control release of a resident cell or its progeny. The device mediates active recruitment, modification, and release of host cells from a material. The bioactive composition is extracellular matrix. Further, a growth factor or a differentiation factor are included as a second bioactive composition. The growth factor is vascular endothelial growth factor, hepatocyte growth factor, or fibroblast growth factor. Or the second bioactive composition is an inhibitor of a molecule.
<P>PROBLEM TO BE SOLVED: To provide a technique for making pore existence inconspicuous by a natural finish with respect to a cosmetic, in more detail, a cosmetic suitable as a foundation cosmetic having correction action on pore.  <P>SOLUTION: The cosmetic comprises (1) 0.005-10 mass% of spherical powder having 3-20 μm particle diameter and (2) 0.005-10 mass% of fibrous titanium dioxide. The spherical powder is preferably a silicic anhydride which may contain a 1-4C alkyl group or a phenyl group as a substituent group replacing oxygen in a silicon-oxygen bond. A silicic anhydride having no porous layer at least on the surface and/or a methylpolysiloxane resin or a methylphenylsiloxane resin which may contain a crosslinking structure is preferable as the spherical powder. The fibrous titanium dioxide has preferably a hollow structure.  <P>COPYRIGHT: (C)2007,JPO&INPIT
Patients receive oral SAHA three times a day on days 1-14. In both arms, treatment repeats every 21 days for up to 17 courses in the absence of disease progression or unacceptable toxicity.
BACKGROUND: Low back pain (LBP) majorly contributes to activity limitations and work absences worldwide. Therefore, a comprehensive knowledge of the risk factors linked to non-specific low back pain (NSLBP) can enable early and timely interventions to achieve long-term improvements. Current study aimed to assess the risk factors associated with the severity of NSLBP patients in Syria.
METHODS: This study used a cross-sectional design and a self-assessment questionnaire to collect data on NSLBP, as well as personal and physical factors, across four provinces in Syria (Damascus, Aleppo, Homs, and Latakia) from November 2021 to September 2022. The assessments incorporated the Short Form 36-Item Health Survey (SF-36), the Visual Analogue Scale (VAS) and Oswestry Disability Index (ODI). Then we examined the relationship between the severity of NSLBP and these potential risk factors. Descriptive statistics were employed to summarize the demographic characteristics of the participants. Additionally, multiple logistic regression analysis was performed to evaluate the risk factors for non-specific low back pain.
RESULTS: The study included a total of 875 patients with NSLBP. The results indicated that patients with primary school education, a high body mass index (BMI), prolonged driving and sitting durations, smoking habits, and recurrent low back pain had higher VAS and ODI scores, as well as lower SF-36 scores (p < 0.01). Additionally, workers and drivers had higher VAS and ODI scores and lower SF-36 scores compared to waiters and patients who lifted objects heavier than 10 kg for more than a quarter of their work time for over 10 years (p < 0.01). The multiple logistic regression analysis revealed that lower education levels, low back pain lasting 1-7 days, chronic low back pain in the past year, smoking, driving for prolonged time, and higher BMI were associated with more severe VAS scores.
CONCLUSION: The severity of NSLBP is related to lower education levels, poor living conditions, strenuous physical labor, inactive lifestyle, and driving for a long time. Additionally, patients with recurrent NSLBP experience more intense pain. To manage these issues, potential interventions could include reducing obesity rates, limiting the duration of hard physical work, limiting driving duration and reducing sedentary behaviors and smoking. These measures may help alleviate the overall burden of NSLBP.
Purified multivalent and lyophilized antivenin and a use method belong to antibody immunity serums that aim at more than two antigens. The invention aims at preparing the multivalent antivenin by a plurality of lyophilized antivenins and the use method. The invention is characterized in that: the antigen-binding fragment F(ab)2 has 60 to 80 percent of lyophilized antiserum, the unit is mg per person, 342.5 to 1035 of vipers, 1177 to 3182 of agkistrodon acutus, 456 to 666 of adders, 1419 to 2128 of king cobras, 220 to 331 of coral snakes, 880 to 1320 of gold banded kraits, 3188 to 4782 of cobras are combined; the optimized combination is as follows: 635 of vipers, 1959 of agkistrodon acutus, 561 of adders, 1774 of king cobras, 276 of coral snakes, 1100 of gold banded kraits and 3985 of cobras. Blood circulation snake venom antiserum and nerves snake venom antiserum are respectively filled and measured. The use method is as follows: the antivenin that is diluted by sodium chloride and an anti-allergic agent, such as chlorphenamine maleate, are injected into muscle or a vein. The antivenin is prepared by only seven antivenins, and can effectively and in time treat injuries caused by various poisonous snakes in our country when the antiserum is directly injected in condition of the undetermined variety of poisonous snakes, and the invention reaches the advanced world level of the antivenin.
INTRODUCTION: Globally, nearly half of all deaths among children under the age of five are linked to undernutrition. These tragic outcomes are most prevalent in low- and middle-income countries. The far-reaching impact of malnutrition affects not only individuals but also their families, communities, and entire nations. By examining underweight, we gain valuable insights into the intricate network of factors influencing child health. Therefore, this study aims to assess underweight prevalence and its associated factors among under-five children in low and lower-middle-income African countries.
METHOD: We conducted a secondary analysis of standard demographic and health surveys in 30 low and lower-middle-income African countries spanning from 2012 to 2022. Our analysis included a total sample of 200,655 children under the age of 5 years. We employed a three-level hierarchical model to assess the determinants of underweight among children in this age group. Measures of association were evaluated using adjusted odds ratios with a 95% confidence interval. Explanatory variables with a p-value less than the level of significance (0.05) were considered statistically significant.
RESULT: The pooled prevalence of underweight among children under the age of five in low and lower-middle income African countries was estimated at 17.60%, with a 95% confidence interval (CI) ranging from 17.44 to 17.77%. The hierarchical analysis identified several factors significantly associated with underweight, including male gender, birth size, maternal body mass index, maternal educational level, household wealth index, antenatal care (ANC) visits, community poverty level, and income level of countries.
CONCLUSION: The high prevalence of underweight among children under the age of five in low and lower-middle income African countries underscores the need for targeted interventions. By addressing individual, community, and country-level factors, we can work toward improving child nutrition and well-being.
TPN Electrolytes (multiple electrolyte additive) helps to maintain normal cellular metabolism during TPN (total parenteral nutrition). Providing electrolytes in appropriate amounts prevents deficiency symptoms which otherwise would occur in their absence.

Cations: Sodium is the principal extracellular cation; it helps maintain motor nerve depolarization, proper fluid balance and normal renal metabolism. Potassium is the principal intracellular cation; it helps transport dextrose across the cell membrane and contributes to normal renal function. Magnesium is an important cofactor for enzymatic reactions and helps to maintain normal CNS (central nervous system) activity and amino acid utilization. Calcium participates in muscle contraction, blood coagulation and helps maintain normal neuromuscular function.

Anions: Chloride is the principal extracellular anion which, along with bicarbonate, is involved in maintaining proper anion balance. Acetate is an important metabolic intermediate in the tricarboxylic acid cycle and is a bicarbonate alternate.

The distribution and excretion of sodium (Na+) and chloride (Cl−) are largely under the control of the kidney which maintains a balance between intake and output.

Approximately 80% of body calcium (Ca++) is excreted in the feces as insoluble salts; urinary excretion accounts for the remaining 20%.

Potassium (K+) is found in low concentration in the plasma and extracellular fluids (3.5 to 5.0 mEq/liter in a healthy adult). Normally about 80% to 90% of the potassium intake is excreted in the urine, the remainder in the stools and to a small extent, in the perspiration. The kidney does not conserve potassium well so that during fasting or in patients on a potassium-free diet, potassium loss from the body continues resulting in potassium depletion.

Magnesium (Mg++) is the second most plentiful intracellular cation. Normal plasma concentration ranges from 1.5 to 2.5 or 3.0 mEq per liter. Magnesium is excreted solely by the kidney at a rate proportional to the plasma concentration and glomerular filtration.

Acetate (CH3COO−) provides bicarbonate (HCO3−) by metabolic conversion in the liver. This has been shown to proceed readily even in the presence of severe liver disease.
Background: The incidence of head and neck cancer (HNC) is increasing slightly. HNC and its treatment may affect general domains of health-related quality of life (HRQoL) and provoke a variety of adverse symptoms and side effects, both during and after treatment. The objective of this study was to compare a person-centred care intervention in terms of HRQoL, disease-specific symptoms or problems, with traditional care as a control group for patients with HNC. Methods: The intervention and control groups comprised 54 and 42 patients, respectively. Outcome measures used were: the EORTC QLQ-C30 and the EORTC QLQ-C35. Both groups answered the questionnaires at baseline and after 4, 10, 18 and 52 weeks from start of treatment. The questionnaires' scores were compared between groups by using independent samples test (Student's t-test) and non-parametric test (Mann-Whitney U Test) for continuous variables. For categorical data, Fisher's exact test was used. Longitudinal data were analysed using repeated measures in covariance pattern models. Results: At baseline, the intervention and control groups were comparable in terms of medical and sociodemographic variables, clinical characteristics, HRQoL and disease-specific symptoms or problems. At all the follow-up points, even during the worst period for the patients, the person-centred-care group consistently reported higher scores than the control group. The differences were numerically but not always statistically significant. When using repeated measures in covariance pattern models, statistically significant results were found for HNC-specific problems, swallowing (p= 0.014), social eating (p=0.048) and feeling ill (p=0.021).
A vascular embolization gelling agent for sustained release of drugs for treating tumors having a drug and a drug carrier. The drugs are antitumor drugs. The drug carrier includes poloxamer polymer and polyvinylpyrrolidone or gel made of the combination, and may be purified before use. The drug carrier accounts for 5-65% of the gel. The particle size of the gel is in the range of 10 nm-150 μm. The embolization agent is a liquid gel at normal temperature, to facilitate direct transcatheter injection, and is rapidly solidified to the gel state in body with the increase of the temperature; it is used to encapsulate different drugs on demand, and can achieve dual efficacy of embolization and drug treatment through local sustained release of the drug. The present invention can be used as the embolization agent for endovascular interventional therapy for transcatheter arterial chemoembolization of various benign and malignant tumors.
<P>PROBLEM TO BE SOLVED: To provide monoclonal antibodies binding to lipoteichoic acid (LTA) of Gram positive bacteria.  <P>SOLUTION: The present invention encompasses a monoclonal antibodies, in which at least a part of variable regions of antibodies is obtained from phage display library containing human antibody sequences, specifically binding to lipoteichoic acid (LTA) of gram-positive bacteria or their fragments. The antibodies also bind to whole bacteria and enhance phagocytosis and killing of the bacteria in vitro. The invention also disclose antibodies having human sequences (chimeric, humanized and human antibodies). The invention also discloses three variable regions contained in the above antibodies.  <P>COPYRIGHT: (C)2008,JPO&INPIT
The physician (n=1) that oversees the UW LUTD Program will assess data from each patients session. Based on the information he gathers from the session, he will complete a feedback form. Each patient's EMG activity will be stored by the video game which will allow the physician to review the patient's performance. Specifically, the physician will look for the minimum relaxation and the maximum contraction levels of the patient throughout play as well as muscular isolation.
A 48-year-old woman presented to the outpatient clinic with a 4-month history of alternating diarrhea and constipation with bloating. Physical examination revealed a body mass index of 22.89 kg/m², normal development, and no tenderness or rebound tenderness in the abdomen. The patient has maintained a stable body size since birth, with a previously healthy status and no history of abdominal surgery or trauma. Endoscopic examination revealed an abnormal channel between the posterior wall of the duodenal bulb to the hepatic flexure of the colon. The patient was managed with conservative treatment, including acid suppression and modulation of the gut microbiota, and was closely monitored. Surgical intervention would only be considered in the event of severe symptoms or complications. Over a five-month follow-up period, the patient's symptoms improved.
Cyclophosphamide can cause myelosuppression (leukopenia, neutropenia, thrombocytopenia and anemia), bone marrow failure, and severe immunosuppression which may lead to serious and sometimes fatal infections, including sepsis and septic shock. Latent infections can be reactivated [see Adverse Reactions (6.2)]. 

Antimicrobial prophylaxis may be indicated in certain cases of neutropenia at the discretion of the managing physician. In case of neutropenic fever, antibiotic therapy is indicated. Antimycotics and/or antivirals may also be indicated. 

Monitoring of complete blood counts is essential during cyclophosphamide treatment so that the dose can be adjusted, if needed. Cyclophosphamide should not be administered to patients with neutrophils ≤1,500/mm3 and platelets < 50,000/mm3. Cyclophosphamide treatment may not be indicated, or should be interrupted, or the dose reduced, in patients who have or who develop a serious infection. G-CSF may be administered to reduce the risks of neutropenia complications associated with cyclophosphamide use. Primary and secondary prophylaxis with G-CSF should be considered in all patients considered to be at increased risk for neutropenia complications. The nadirs of the reduction in leukocyte count and thrombocyte count are usually reached in weeks 1 and 2 of treatment. Peripheral blood cell counts are expected to normalize after approximately 20 days. Bone marrow failure has been reported. Severe myelosuppression may be expected particularly in patients pretreated with and/or receiving concomitant chemotherapy and/or radiation therapy.
regarding patient registry; a prior G power analysis was done. 24 per group was determined to achieve 80% power to detect a difference of 60 min in time to first rescue analgesia between the two groups with a significance level (α) of 0.05 using a two-sided two-sample t-test; 25 patients were included per group to replace any dropouts.

- Statistical analysis: Data will be analyzed through SPSS (Statistical Package for Social Sciences). Program version 22. Distribution of data will be first tested by the Shapiro test. Data will be presented as the mean and standard deviation (SD), median and range or numbers and percentages. For normally distributed data, the unpaired t-test will be used to compare the mean values of both groups. For pain score, Mann Whitney U test will be used. Fisher's exact test will be used for comparison of categorical data. The P value ≤ 0.05 will be considered as the level of statistical significance.
Patients will receive four cycles of GCaP administered every 21 days. Panitumumab will be administered intravenously at a dose of 9mg/kg on day 1. Gemcitabine 1,000 mg/m2 on day 1 and 8 and carboplatin AUC 4.5 on day 1 will be administered intravenously on a 21-day cycle. A total of four cycles of therapy will be administered at 21-day intervals followed by radical cystectomy.